Group items tagged

Global logistics company, JAS has received the Wholesale Distribution Authorisation (WDA(H)) license from the UK's Medicine and Healthcare Products Regulatory Agency (MHRA) for its Pharma and Healthcare Division. In a press release issued on Thursday (22 February), the company said that securing the license empowers its UK healthcare division to "seamlessly connect" with its more than 40 GDP (Good Distribution Practice) certified overseas stations, strengthening its capabilities for handling pharmaceutical shipments. Headquartered in Atlanta, Georgia, USA, the company boasts a team of over 7,000 professionals, with operations spanning over 100 countries. Adrian Frodsham, Regional Director for JAS, said that they were granted the WDA(H) license after a "stringent audit process." "JAS UK's pharma and healthcare division prides itself of offering innovative solutions for the international delivery of pharmaceutical products, further enhancing the growth of our pre-established healthcare division," he added.

Indiana Medical Licensing Board Mandatory Topic Course Bundle for Physicians. The two online courses cover one topic per the Indiana Medical Board license renewal requirements

The collapse of the three trading entities in the Converse Pharma Group (Testerworld Limited, Doncaster Pharmaceuticals Group Limited and Eclipse Generics Limited) (the Group) in May 2022 undoubtedly caused ripples throughout the pharmacy industry. The Group, a major supplier of pharmaceuticals, had a combined turnover over £300m, employed 1,000 staff members and supplied over 4,000 pharmacies throughout the country. The Group is licensed and regulated by the MHRA. At the beginning of 2021, a breach of the MHRA licensing regulations caused a temporary (but prolonged) cessation of trading. The Group was able to secure the ongoing support of its secured creditors during this time, however, when the licenses were subsequently reinstated, they came with restrictions. Unfortunately for the Group, the period of the suspension and the subsequent restrictions over the licences caused a significant reduction in revenue, from which the Group was unable to recover. Ultimately, by May this year, the companies in the Group had exhausted their working capital and had no prospect of raising the funding they required to continue to trade.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

Georgia Licensed Practical Nurse CE Package is organized by AchieveCE

Restricting sales of vape products to pharmacies is not a solution to curb illegal sales of vape among underage adults, said UK Vaping Industry Association (UKVIA). In an oral evidence at the House of Commons on 'Youth Vaping' called by the Health and Social Care Select Committee (HSSC) to figure out action needed to reduce vaping among those under 18. Rachael Maskell, York Central MP's suggested on vape products being available from licensed pharmacies. Marcus Saxton, Chairman, Independent British Vape Trade Association (IBVTA) said: "We are calling for further regulation to tighten up what has now been an extreme growth in single-use products. If you put them into those environments, as New Zealand and Australia are telling us, the perception of the public is that, while they can buy tobacco freely anywhere, the vaping product that is up to 95% safer is licensed through a pharmacy. It makes absolutely no sense. The negative consequence of considering such a thing will take us backwards years."

Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes on Tuesday (27 June). "There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM)," said DHSC. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to normal until at least mid-2024. Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options.

An off licence has had its licence suspended after a team from Ealing Council found unmarked illegal items on the premises. Harcharan Singh claimed he was allowing locals to store their medicines at his shop, King Quality Foods, while they visited the nearby temple. Singh's representative, Surendra Panchal, told the panel about the reasons which baffled the chair of the licensing sub-committee, Cllr Anthony Kelly. Cllr Kelly did not comprehend how a package of drugs would be difficult to fit in someone's bag, pocket, or car. The officials found drugs including high blood pressure and diabetes medication at the store.

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sulfasalazine 250mg in 5ml oral suspension sugar free; Pilocarpine hydrochloride 4% eye drops; Fluticasone 50microgram / Salmeterol 25microgam (Combisal) pressurised metered dose inhaler (pMDI); and Dalteparin (Fragmin) 10,000units/1mL solution for injection ampoule on Wednesday (21 December). "Sulfasalazine 250mg/5ml oral suspension sugar free is out of stock from w/c 19th December until early June 2023. Sulfasalazine 500mg non-enteric coated tablets remain available "IPS Pharma, Nova Labs, and Rokshaw have currently confirmed they can manufacturer sulfasalazine 250mg/5ml oral suspension," said DHSC. Pilocarpine 4% eye drops are out of stock until w/c 26th December 2022. Alternative strengths of pilocarpine (1% and 2%) eye drops remain available and will be able to support increased demand. Specials of pilocarpine 4% preservative free eye drops are available if the licensed alternatives are not suitable. For off-label use of the 4% drops in the treatment of xerostomia (dry mouth) in palliative care, pilocarpine 5mg tablets are available and are licensed for this indication.

Save Local Now offers list of all business for church, insurance, finance, salon, day spa, pizza, school, eye care, dentist, jewelers, accountant, travel, landscape, fitness, day care, legal services, restaurants, parks, license agency, retail and many more available in Hilliard OH 43026.

Primary Care and Specialty Care Online CME/CE Courses for Physicians and Nurses for Medical License Renewal. Search by State and Specialty Course Bundles.

Pennsylvania State Board of Medicine Mandatory Topic Course Bundle for Physicians. The six online courses cover 4 topics per PA Medical Board license renewal requirements.

Minnesota Board of Nursing Required Courses Bundle for License Renewal. Helps you attain the Minnesota Board of Nursing-required mandatory topic CE credits.

Iowa Board of Medicine Mandatory Topic Course Bundle for Physicians. The four online courses cover two topics per the Iowa Medical Board license renewal requirements.

Vermont Medical Board Required Courses Bundle for License Renewal. Helps you attain the Vermont Board of Medicine-required mandatory topic CME credits

Connecticut Medical Examining Board Required Courses Bundle for License Renewal. Helps you attain the CT Medical Examining Board-required mandatory topic CME credits.